Deciphera Pharmaceuticals (NASDAQ:DCPH) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical (OTCMKTS:OPHLY). This deal has ONO acquiring ...
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Deciphera Pharmaceuticals, Inc. (DCPH) one of those stocks right now? By taking a ...
Deciphera Pharmaceuticals, Inc. DCPH reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had ...
It has been about a month since the last earnings report for Deciphera Pharmaceuticals, Inc. . Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative ...
Deciphera Pharmaceuticals, Inc. (DCPH Quick Quote DCPH - Free Report) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of ...
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results